Zavesca Actelion Pharmaceuticals - Treatment for Type 1 Gaucher Disease
Zavesca is in a class of drugs known as substrate reduction therapy (SRT), which reduces the amount of glycosphingolipid (GSL) production. Zavesca is indicated for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.Posted: July 2003
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
